209 related articles for article (PubMed ID: 37598282)
1. Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma.
Sircar A; Singh S; Xu-Monette ZY; Coyle KM; Hilton LK; Chavdoula E; Ranganathan P; Jain N; Hanel W; Tsichlis P; Alinari L; Peterson BR; Tao J; Muthusamy N; Baiocchi R; Epperla N; Young KH; Morin R; Sehgal L
Leukemia; 2023 Oct; 37(10):2094-2106. PubMed ID: 37598282
[TBL] [Abstract][Full Text] [Related]
2. CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.
Kagiyama Y; Fujita S; Shima Y; Yamagata K; Katsumoto T; Nakagawa M; Honma D; Adachi N; Araki K; Kato A; Inaki K; Ono Y; Fukuhara S; Kobayashi Y; Tobinai K; Kitabayashi I
Cancer Sci; 2021 Jun; 112(6):2314-2324. PubMed ID: 33792119
[TBL] [Abstract][Full Text] [Related]
3. LncRNA MALAT1 promotes development of mantle cell lymphoma by associating with EZH2.
Wang X; Sehgal L; Jain N; Khashab T; Mathur R; Samaniego F
J Transl Med; 2016 Dec; 14(1):346. PubMed ID: 27998273
[TBL] [Abstract][Full Text] [Related]
4. EZH2 expression is associated with inferior overall survival in mantle cell lymphoma.
Martinez-Baquero D; Sakhdari A; Mo H; Kim DH; Kanagal-Shamanna R; Li S; Young KH; O'Malley DP; Dogan A; Jain P; Wang ML; McDonnell TJ; Miranda RN; Vega F; Medeiros LJ; Ok CY
Mod Pathol; 2021 Dec; 34(12):2183-2191. PubMed ID: 34376807
[TBL] [Abstract][Full Text] [Related]
5. ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy.
Chen Z; Teo AE; McCarty N
Clin Cancer Res; 2016 Jan; 22(1):187-99. PubMed ID: 26350264
[TBL] [Abstract][Full Text] [Related]
6. Wedelolactone Targets EZH2-mediated Histone H3K27 Methylation in Mantle Cell Lymphoma.
Romanchikova N; Trapencieris P
Anticancer Res; 2019 Aug; 39(8):4179-4184. PubMed ID: 31366503
[TBL] [Abstract][Full Text] [Related]
7. Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma.
Thieme E; Liu T; Bruss N; Roleder C; Lam V; Wang X; Nechiporuk T; Shouse G; Danilova OV; Bottomly D; McWeeney SK; Tyner JW; Kurtz SE; Danilov AV
Cell Death Dis; 2022 Mar; 13(3):246. PubMed ID: 35296646
[TBL] [Abstract][Full Text] [Related]
8. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.
Yang Q; Chen LS; Neelapu SS; Miranda RN; Medeiros LJ; Gandhi V
Blood; 2012 Oct; 120(17):3491-500. PubMed ID: 22955922
[TBL] [Abstract][Full Text] [Related]
9. Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment.
Papin A; Le Gouill S; Chiron D
Leuk Lymphoma; 2018 May; 59(5):1064-1072. PubMed ID: 28758825
[TBL] [Abstract][Full Text] [Related]
10. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.
Lee J; Zhang LL; Wu W; Guo H; Li Y; Sukhanova M; Venkataraman G; Huang S; Zhang H; Alikhan M; Lu P; Guo A; Galanina N; Andrade J; Wang ML; Wang YL
Blood Adv; 2018 Aug; 2(16):2039-2051. PubMed ID: 30115641
[TBL] [Abstract][Full Text] [Related]
11. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
Sun B; Shah B; Fiskus W; Qi J; Rajapakshe K; Coarfa C; Li L; Devaraj SG; Sharma S; Zhang L; Wang ML; Saenz DT; Krieger S; Bradner JE; Bhalla KN
Blood; 2015 Sep; 126(13):1565-74. PubMed ID: 26254443
[TBL] [Abstract][Full Text] [Related]
12. B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma.
Dai B; Grau M; Juilland M; Klener P; Höring E; Molinsky J; Schimmack G; Aukema SM; Hoster E; Vogt N; Staiger AM; Erdmann T; Xu W; Erdmann K; Dzyuba N; Madle H; Berdel WE; Trneny M; Dreyling M; Jöhrens K; Lenz P; Rosenwald A; Siebert R; Tzankov A; Klapper W; Anagnostopoulos I; Krappmann D; Ott G; Thome M; Lenz G
Blood; 2017 Jan; 129(3):333-346. PubMed ID: 27864294
[TBL] [Abstract][Full Text] [Related]
13. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
Chiron D; Di Liberto M; Martin P; Huang X; Sharman J; Blecua P; Mathew S; Vijay P; Eng K; Ali S; Johnson A; Chang B; Ely S; Elemento O; Mason CE; Leonard JP; Chen-Kiang S
Cancer Discov; 2014 Sep; 4(9):1022-35. PubMed ID: 25082755
[TBL] [Abstract][Full Text] [Related]
14. [Expression of MiR101 and EZH2 in Patients with Mantle Cell Lymphoma and Its Clinical Significance].
Lin YL; Zou ZK; Su HY; Huang YQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Jun; 27(3):820-826. PubMed ID: 31204938
[TBL] [Abstract][Full Text] [Related]
15. Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1.
Sekihara K; Saitoh K; Han L; Ciurea S; Yamamoto S; Kikkawa M; Kazuno S; Taka H; Kaga N; Arai H; Miida T; Andreeff M; Konopleva M; Tabe Y
Oncotarget; 2017 May; 8(21):34552-34564. PubMed ID: 28388555
[TBL] [Abstract][Full Text] [Related]
16. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
[TBL] [Abstract][Full Text] [Related]
17. Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy.
Silkenstedt E; Arenas F; Colom-Sanmartí B; Xargay-Torrent S; Higashi M; Giró A; Rodriguez V; Fuentes P; Aulitzky WE; van der Kuip H; Beà S; Toribio ML; Campo E; López-Guerra M; Colomer D
J Exp Clin Cancer Res; 2019 Nov; 38(1):446. PubMed ID: 31676012
[TBL] [Abstract][Full Text] [Related]
18. Targeting EZH1/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57
Li W; Bi C; Han Y; Tian T; Wang X; Bao H; Xu X; Zhang X; Liu L; Zhang W; Gao H; Wang H; Zhang H; Meng B; Wang X; Fu K
Cancer Biol Med; 2019 Aug; 16(3):530-541. PubMed ID: 31565482
[TBL] [Abstract][Full Text] [Related]
19. Dual targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol.
Alinari L; Prince CJ; Edwards RB; Towns WH; Mani R; Lehman A; Zhang X; Jarjoura D; Pan L; Kinghorn AD; Grever MR; Baiocchi RA; Lucas DM
Clin Cancer Res; 2012 Sep; 18(17):4600-11. PubMed ID: 22791882
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.
Xargay-Torrent S; López-Guerra M; Montraveta A; Saborit-Villarroya I; Rosich L; Navarro A; Pérez-Galán P; Roué G; Campo E; Colomer D
Clin Cancer Res; 2013 Feb; 19(3):586-97. PubMed ID: 23231952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
